A drug discovery company model that develops its own technologies and products
First written in FY2016. 6 of 7 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「A drug discovery company conducts drug discovery focused on specific areas based on its proprietary drug discovery platform technology, also known as a drug discovery engine, thereby creating both technologies and products in-house. We are pursuing a business model that differs substantially from that of companies without a drug discovery platform, which introduce compounds under development from external sources and, after a certain amount of development, out-license them to pharmaceutical companies.」
The company continues to pursue a drug discovery company model that creates both technologies and products in-house based on its proprietary drug discovery engine. - FY2023RestatedAnnual report
「A drug discovery company conducts drug discovery focused on specific areas based on its proprietary drug discovery platform technology, also known as a drug discovery engine, thereby creating both technologies and products in-house. We are pursuing a business model that differs substantially from that of companies without a drug discovery platform, which introduce compounds under development from external sources and, after a certain amount of development, out-license them to pharmaceutical companies.」
The company has reaffirmed its drug discovery company model of creating both technologies and candidate compounds in-house based on its proprietary drug discovery engine. - FY2022RestatedAnnual report
「A drug discovery company conducts drug discovery focused on specific areas based on its proprietary drug discovery platform technology, also known as a drug discovery engine, thereby creating both technologies and products in-house. We are pursuing a business model that differs substantially from that of companies without a drug discovery platform, which introduce compounds under development from external sources and, after a certain amount of development, out-license them to pharmaceutical companies.」
The company has reaffirmed its drug discovery company model of creating both technologies and products in-house based on its proprietary drug discovery engine. - FY2021RestatedAnnual report
「A drug discovery company conducts drug discovery focused on specific areas based on its proprietary drug discovery platform technology, also known as a drug discovery engine, thereby creating both technologies and products in-house. We are pursuing a business model that differs substantially from that of companies without a drug discovery platform, which introduce compounds under development from external sources and, after a certain amount of development, out-license them to pharmaceutical companies.」
The company continues to pursue a drug discovery company model that creates both technologies and products in-house based on its proprietary drug discovery engine. - FY2020RestatedAnnual report
「A drug discovery company conducts drug discovery focused on specific areas based on its proprietary drug discovery platform technology, also known as a drug discovery engine, thereby creating both technologies and products in-house. We are pursuing a business model that differs substantially from that of companies without a drug discovery platform, which introduce compounds under development from external sources and, after a certain amount of development, out-license them to pharmaceutical companies.」
The company continues to pursue a drug discovery company model that creates both technologies and products in-house based on its proprietary drug discovery engine. - FY2017RestatedAnnual report
「We are pursuing a business model aimed at generating added value as a drug discovery company that creates both its technologies and products in-house by operating on the basis of our proprietary drug discovery engine.」
The company continues to pursue a drug discovery company model that creates both technologies and candidate compounds in-house. - FY2016First statedAnnual report
「A drug discovery company conducts drug discovery focused on specific areas based on its proprietary drug discovery platform technology, also known as a drug discovery engine, thereby creating both technologies and products in-house. We are pursuing a business model that differs substantially from that of companies without a drug discovery platform, which introduce compounds under development from external sources and, after a certain amount of development, out-license them to pharmaceutical companies.」
The company presents a business model that creates both its proprietary drug discovery platform technology and candidate compounds in-house, thereby increasing corporate value.